1. Home
  2. ZNTL vs GAMB Comparison

ZNTL vs GAMB Comparison

Compare ZNTL & GAMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZNTL
  • GAMB
  • Stock Information
  • Founded
  • ZNTL 2014
  • GAMB 2006
  • Country
  • ZNTL United States
  • GAMB Jersey
  • Employees
  • ZNTL N/A
  • GAMB N/A
  • Industry
  • ZNTL Biotechnology: Pharmaceutical Preparations
  • GAMB Services-Misc. Amusement & Recreation
  • Sector
  • ZNTL Health Care
  • GAMB Consumer Discretionary
  • Exchange
  • ZNTL Nasdaq
  • GAMB Nasdaq
  • Market Cap
  • ZNTL 105.8M
  • GAMB N/A
  • IPO Year
  • ZNTL 2020
  • GAMB 2021
  • Fundamental
  • Price
  • ZNTL $1.49
  • GAMB $8.06
  • Analyst Decision
  • ZNTL Buy
  • GAMB Strong Buy
  • Analyst Count
  • ZNTL 7
  • GAMB 8
  • Target Price
  • ZNTL $8.46
  • GAMB $15.38
  • AVG Volume (30 Days)
  • ZNTL 830.4K
  • GAMB 911.3K
  • Earning Date
  • ZNTL 11-11-2025
  • GAMB 11-13-2025
  • Dividend Yield
  • ZNTL N/A
  • GAMB N/A
  • EPS Growth
  • ZNTL N/A
  • GAMB N/A
  • EPS
  • ZNTL N/A
  • GAMB 0.40
  • Revenue
  • ZNTL $26,865,000.00
  • GAMB $147,655,000.00
  • Revenue This Year
  • ZNTL N/A
  • GAMB $38.38
  • Revenue Next Year
  • ZNTL N/A
  • GAMB $11.89
  • P/E Ratio
  • ZNTL N/A
  • GAMB $20.34
  • Revenue Growth
  • ZNTL N/A
  • GAMB 27.57
  • 52 Week Low
  • ZNTL $1.01
  • GAMB $7.93
  • 52 Week High
  • ZNTL $5.44
  • GAMB $17.14
  • Technical
  • Relative Strength Index (RSI)
  • ZNTL 43.18
  • GAMB 31.88
  • Support Level
  • ZNTL $1.60
  • GAMB $7.93
  • Resistance Level
  • ZNTL $2.02
  • GAMB $8.46
  • Average True Range (ATR)
  • ZNTL 0.13
  • GAMB 0.24
  • MACD
  • ZNTL -0.04
  • GAMB 0.05
  • Stochastic Oscillator
  • ZNTL 5.36
  • GAMB 14.89

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: